[18F]FDDNP performed better than [18F] Florbetapir to distinguish transthyretin cardiac amyloidosis (TTR-CA) patients from healthy controls: an ex vivo study.
about
[18F]FDDNP performed better than [18F] Florbetapir to distinguish transthyretin cardiac amyloidosis (TTR-CA) patients from healthy controls: an ex vivo study.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh-hant
name
[18F]FDDNP performed better th ...... hy controls: an ex vivo study.
@en
[18F]FDDNP performed better th ...... nsthyretin cardiac amyloidosis
@nl
type
label
[18F]FDDNP performed better th ...... hy controls: an ex vivo study.
@en
[18F]FDDNP performed better th ...... nsthyretin cardiac amyloidosis
@nl
prefLabel
[18F]FDDNP performed better th ...... hy controls: an ex vivo study.
@en
[18F]FDDNP performed better th ...... nsthyretin cardiac amyloidosis
@nl
P2093
P50
P1476
[18F]FDDNP performed better th ...... thy controls: an ex vivo study
@en
P2093
Anne-Claire Dupont
Michel Slama
Nicolas Arlicot
Rana Ben-Azzouna
Rudy Bidault
P2888
P304
P356
10.1186/1750-1172-10-S1-P38
P433
P577
2015-11-02T00:00:00Z
P6179
1017803017